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Abstract
Background: Cyclooxygenase-2 (COX-2, PTGS2) is an enzyme involved in the synthesis of prostaglandins and
thromboxanes, which are regulators of biologic processes such as inflammation, cell proliferation and angiogenesis.
COX-2 over-expression was reported in many (pre) malignant tissues, but data strongly vary and seem to depend
on the methodology used.
Methods: Normal colorectal mucosa and paired cancerous tissue from 60 patients with colorectal cancer was
investigated for the levels of COX-2 mRNA by real-time quantitative Polymerase Chain Reaction (qPCR). COX-2 levels
were expressed relative to either: tissue weight or levels of the housekeeping genes beta-2 microglobulin (B2M)
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Results: COX-2 mRNA levels, normalized with respect to tissue weight or mRNA levels of the housekeeping genes
B2M or GAPDH, were over-expressed in 80%, 70% and 40% of the colorectal tumor tissues, as compared to the
paired adjacent normal colorectal mucosa samples, respectively. Highest mRNA COX-2 ratios tumor/normal were
measured when expressed per mg tissue (mean ratio 21.6). When normalized with respect to the housekeeping
genes B2M or GAPDH, mean tumor/normal ratios were 16.1 and 7.5, respectively.
Conclusion: Expression of COX-2 mRNA levels per mg tissue is most simple in comparison to normalization with
respect to the housekeeping genes B2M or GAPDH. Levels of COX-2 mRNA are found over-expressed in almost 80%
of the colorectal tumors, compared to paired adjacent normal colorectal mucosa, suggesting a role of COX-2 as a
potential biomarker for cancer risk, whereas inhibitors of COX-2 could be of value in chemoprevention of colon
cancer.
Background
The development of colorectal cancer is a multistep
process, where mutations may occur in the oncogenes
K-ras and APC, or in the tumor suppressor gene p53,
causing cell degeneration and uncontrolled cell prolifera-
tion. Cell proliferation is pivotal in tumorigenesis and
cyclooxygenases (COXs) are important regulatory en-
zymes in this process. Cyclooxygenases catalyze the con-
version of free arachidonic acid into prostaglandin H2,
which is the precursor of other prostaglandins and
thromboxanes. These regulatory compounds play a role
in various biological processes such as cell proliferation,
angiogenesis, immune function and inflammation, which
are all crucial in the development or progression of neo-
plasms [1].
The human COX family consists of three members,
COX 1–3. COX-1 is found in most tissues and plays a
role in homeostasis of many physiologic processes.
COX-3 is an alternative splice product of COX-1 and is
involved in the regulation of pain and fever. COX-2 is
an inducible enzyme, whose expression can be influ-
enced by pro-inflammatory and mitogenic stimuli like
cytokines and growth factors. COX-2 plays an important
role in the development of metaplastic and dysplastic
tissue, as well as in the development and progression of
cancer, by involvement in the regulation of cell prolifera-
tion, cell transformation, tumor growth, tumor metasta-
sis and invasion [1,2].
Over-expression of COX-2 has been associated with
various premalignant and malignant lesions of epithelial
origin, in particular in organs of the gastrointestinal tract
[3-8]. Tumors with high levels of COX-2 seem to be
more aggressive [5] and patients bearing those tumors
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had a significantly reduced survival [9]. In addition, after
drug-induced suppression of COX-2 levels in laboratory
animals subjected to entero-esophageal reflux, less ani-
mals developed esophageal adenocarcinoma [10]. This
is of particular interest since more or less specific in-
hibitors of COX-2, such as various non-steroidal anti-
inflammatory drugs (NSAIDs), have been or are being
developed, that could have a role in the chemopreven-
tion of gastrointestinal neoplasms [6]. Evidence is accumu-
lating that a considerable reduction in the development
of adenomatous polyps or colorectal cancer could be
achieved in individuals regularly taking NSAIDs [6].
Although most NSAIDs do not specifically inhibit COX-2,
the findings of over-expression of COX-2 in many (pre)
malignant tissues, in combination with the reported bene-
ficial effects of NSAIDs on cancer prevention, suggests that
inhibition of COX-2 may be crucial in this process.
Since alterations in COX-2 levels may be pivotal in in-
fluencing the development of colorectal cancer [11], it is
crucial that COX-2 levels can be estimated in a reliable
way. Different techniques were used to investigate the
COX-2 levels in colorectal neoplasms, yielding a large
variety in outcomes. Semi-quantitative immunohisto-
chemical staining for COX-2 was applied, thereby using
different COX-2 antibodies [3,12-15]. Quantitative assay
of COX-2 mRNA levels was performed [4,16-18], whereas
both techniques were combined in some studies [12-15].
Large variations in the colorectal COX-2 expression levels
were reported. In most studies, higher levels of COX-2
mRNA were demonstrated in the tumor, compared to the
normal colorectal tissue [4,14,15,17,18], however sample
sizes generally were small. In two larger studies, no ele-
vated COX-2 mRNA levels in the tumor were reported
[12,16]. Furthermore, in the studies where mRNA levels
were assayed, most often no paired samples of normal and
cancerous tissue from the same patient were investigated.
In addition COX-2 mRNA levels were normalized with re-
spect to different housekeeping genes.
The aim of the present study was to quantify the COX-2
mRNA levels in 60 paired samples of non-necrotic tumor
tissue and corresponding normal colorectal mucosa, taken
at least 5 cm distant from the tumor. The COX-2 mRNA
levels will be expressed per mg tissue, as well as relative to
the levels of two different housekeeping genes, beta-2
microglobulin (B2M) and glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH).
Methods
Normal colorectal mucosa and tumor tissue of 60 patients
with sporadic colorectal cancer was included in this study.
These tissues were obtained as rest material after surgical
intervention and tissues were processed and assayed an-
onymously. Patients did not receive any treatment just
before surgery. Rest material after resection for colorectal
cancer was collected at the Department of Gastroenter-
ology, Radboud University Nijmegen Medical Center
(RUNMC), in the period 1999–2002. Immediately after
resection, the tissue was cooled on ice and transported to
the Pathology Department, where the pathologist inspected
the tissue within 30 min. Representative specimens of
macroscopically vital, non-necrotic tumor tissue and nor-
mal colorectal mucosa, taken at least 5 cm distant from the
tumor, were obtained. Specimens were transported on ice
to the laboratory and the tissue was washed with ice-cold
phosphate buffered saline (PBS), cut in small pieces, frozen
in liquid nitrogen and stored at −80°C until use. Ethical
approval for the anonymous use of colorectal rest material
was obtained by the RUNMC medical ethical review
committee.
Assay of COX-2 mRNA levels
Tissue was kept frozen while small samples (10–20 mg
tissue) were cut off for mRNA analyses. From normal
colon tissue, only mucosa was scraped off from the fro-
zen samples. The normal- and tumor tissue samples
were put into separate vials, weighed, and immediately
thereafter 0.5 ml TRIzol (Life Technologies, Pailey, UK)
was added. The within day variation of weighing tis-
sues in the 10–50 mg range, using a Mettler AC100
precision weighing device (Mettler Instruments, Tiel,
the Netherlands), was estimated to be 0.2-0.6%. Tissue
was homogenized by 10 strokes with a Teflon pestle. RNA
was isolated according to the instructions of the manu-
facturer (Life Technologies). Subsequently, 1 μg RNA
was converted into cDNA, using the Roche Transcrip-
tor cDNA synthesis kit, according to the instructions
of the manufacturer (Roche Diagnostics, Almere, the
Netherlands). Detection and quantification of mRNAs
was performed by real-time quantitative PCR (qPCR)
using the CFX96 Real-Time PCR Detection System
(Bio-Rad Laboratories, Veenendaal, the Netherlands).
Sequences of the primers were designed using Primer3
software (http://primer3.ut.ee/). Primers are: COX-2, 5’-
CCGGGTACAATCGCACTTAT-3’ and 5’-GGCGCT
CAGCCATACAG-3’ (Isogen Life Science, Maarssen, The
Netherlands); GAPDH, 5’-GAAGGTGAAGGTCGGAGT
CA-3’ and 5’-TTGAGGTCAATGAAGGGGTC-3’ (Isogen
Life Science); B2M, 5’-ATGAGTATGCCTGCCGTGTG-
3’ and 5’-CCAAATGCGGCATCTTCAAAC-3’ (Biolegio,
Nijmegen, The Netherlands). Pairs of primers are designed
to localize on different exons.
PCR products of COX-2 and GAPDH were detected
with SYBR Green (Molecular Probes, Life Technologies,
Bleiswijk, the Netherlands). For detection of B2M, a specific
molecular beacon 5’-FAM-CGCGTCGTGGGATGGAGA
CATGTAAGCAGACGCG-Dabcyl-3’ was used (Biolegio).
The annealing temperatures of the COX-2, GAPDH and
B2M primers were 65.0˚C, 59.0˚C and 60.5˚C, respectively.
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Specificity of the PCR products of COX-2, GAPDH
and B2M was confirmed by melting curve analysis and
agarose gel electrophoresis. All real time qPCR analyses
were performed in triplicate.
Statistics
Real time qPCR data were converted to linear data by
calculating the 2-Ct values when data are expressed per
mg tissue, and by calculating the 2-ΔCt values for B2M
and GAPDH normalized data. Data are expressed as ar-
bitrary units or as ratios of COX-2 expression (tumor/
normal mucosa). Statistical analyses were performed
using GraphPad Prism, version 4.00 (GraphPad Software
Inc., La Jolla, CA, USA).
Results
Clinical data of the patients with colorectal cancer, who’s
tissue was used in this study, are summarized in Table 1.
Sixty paired samples of normal colorectal mucosa and
corresponding tumor tissue were analyzed for COX-2
mRNA expression. Levels of COX-2 mRNA, measured
in triplicate, were expressed per mg tissue weight or the
expression was normalized with respect to mRNA levels
of the housekeeping genes B2M and GAPDH. Mean ex-
pression of COX-2 mRNA was higher in colon tumor
tissue, compared to the corresponding normal colorectal
mucosa. However, COX-2 mRNA ratios tumor/normal
clearly were dependent on the standardization used.
Highest mean COX-2 ratios tumor/normal were ob-
served when normalized with respect to tissue weight
(mean ratio 21.6), followed by normalization with re-
spect to the housekeeping genes B2M (mean ratio 16.1)
or GAPDH (mean ratio 7.5); results are shown in Table 2.
The COX-2 mRNA expression levels in normal colorec-
tal mucosa and corresponding tumor tissue, normalized
with respect to either tissue weight or the housekeeping
genes B2M and GAPDH, are depicted in Figure 1.
Ratios of COX-2 mRNA expression in tumor/normal
colorectal mucosa, normalized with respect to tissue
weight, correlated best with the corresponding ratios
normalized for B2M (R = 0.952; P < 0.0001), and to a lesser
extent with those normalized for GAPDH (R = 0.830;
P < 0.0001). Ratios of COX-2 mRNA expression (tumor/
normal) normalized with respect to tissue weight were not
associated with gender (men vs. women, P = 1.0), tumor
localization (left sided vs. right sided colon, P = 0.37),
tumor grade (T2 vs. T3, P = 0.80; T2 vs. T3/T4, P = 0.57)
or lymph node metastases (0 vs. N1/N2, P = 0.14).
Discussion
COX-2 catalyzes the conversion of free arachidonic acid
into prostaglandin H2, the precursor of other prostaglan-
dins and thromboxanes. These compounds are pivotal in
the regulation of cell proliferation, angiogenesis, immune
function and inflammation, which may all contribute to
the development and progression of neoplasms [1].
An important item in the measurements of COX-2
mRNA expression is the standardization. Standardization
against tissue weight, with a variation of 0.2-0.6% in the
weighing results when using a precision weighing device,
is more accurate as compared to the reported variation of
0.7-5.3% for a quantitative real time PCR assay, by per-
forming 3 repeats within one run [19].
Table 1 Characteristics of the patients with sporadic
colorectal cancer
Variable Patients
Number 60
Men/Women 34/26
Mean age (range) 65 (23–90) years
Tumor localization*
-left colon 44
-right colon 16
Tumor stage**
-T2 12
-T3 43
-T4 5
-lymph node metastases (N1/N2) 21 (12/9)
-distant metastases (M1) 5
Differentiation grade***
-well 1
-moderate 56
-poor 2
*Left-sided colon: colon descendens, rectum and sigmoid; right sided colon:
cecum, colon ascendens, colon transversum.
**Tumor staging was done according to the TNM classification.
***Note that for one tumor sample the differentiation grade was unknown.
Table 2 Ratios of COX-2 mRNA expression in paired
colorectal tumor/normal mucosa, normalized with respect
to tissue weight or to the levels of the housekeeping
genes B2M or GAPDH
Tissue weight B2M GAPDH
Number of pairs N = 60 N = 60 N = 55*
Mean ratio 21.6 16.1 7.5
Range 0.01-595.3 0.01-525.5 0.00-150.9
Ratio >1 (%)** 46 (77%) 42 (70%) 22 (40%)
Ratio <1 (%)*** 14 (23%) 18 (30%) 33 (60%)
B2M, beta-2 microglobulin.
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
*Note that GAPDH was not detectable or the analysis did not succeed in
5 cases.
**Ratio > 1 means that COX-2 expression is higher in colorectal tumor tissue
compared to paired normal mucosa.
***Ratio < 1 means that COX-2 expression is lower in colorectal tumor tissue
compared to paired normal mucosa.
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Several studies reported that the COX-2 expression
was elevated in colorectal tumors, in comparison to nor-
mal colorectal tissue. However, different techniques were
used for estimating the COX-2 levels; semi-quantitative
immunohistochemical staining of COX-2, making use of
different COX-2 antibodies [3,12-15], quantitative PCR
assay of COX-2 mRNA [4,16-18], or both techniques
were applied simultaneously [12,14,15]. Immunohisto-
chemical studies generally showed more staining in the
tumor as compared to the normal colorectal mucosa,
however staining positivity in the tumor varied from 35
to 62% in sporadic colorectal cancers [12,14] to 100%
staining positivity in colorectal tumors from patients
with familial adenomatous polyposis [13]. Variations in
results on COX-2 mRNA analyses were also large.
Again, in most studies COX-2 mRNA was found ele-
vated in the tumor, however sample numbers were small
[4,14,15,17,18]. In two larger studies, investigating 99
and 46 tumor samples respectively, no elevated COX-2
mRNA levels in the tumor were reported [12,16]. In
most mRNA studies however, no paired samples of
normal and cancerous tissue, obtained from the same
patient, were investigated. In addition, COX-2 mRNA
levels were normalized relative to the expression of one
housekeeping gene, whereas the choice of which house-
keeping gene was used also differed between the various
studies.
Recently Carvalho et al. showed that COX-2 mRNA
was up-regulated in an age-dependent fashion in colorec-
tal carcinoma as compared to adenoma [20]. However, it
needs to be further elucidated, whether the COX-2 levels
in colorectal adenomas are elevated compared to normal
mucosa. Eberhart et al. [4] reported elevated COX-2 levels
in 3 of 6 colorectal adenomas compared with paired nor-
mal mucosa. Nosho et al. [14] found an over-expression of
COX-2 mRNA in only 42% of the colorectal tumors inves-
tigated, being 63 adenomas and 27 carcinomas. In com-
parison with our data, where over-expression in 77% of
colorectal carcinomas is noticed, this suggests that over-
expression of COX-2 is lower in colorectal adenomas than
Figure 1 COX-2 expression in colorectal tissue.
Roelofs et al. BMC Gastroenterology 2014, 14:1 Page 4 of 6
http://www.biomedcentral.com/1471-230X/14/1
in carcinomas, and that expression is increasing some-
where in the stage between adenoma and carcinoma. This
could plead for the potential use of COX-2 mRNA
levels in feces, as a potential non-invasive marker for
colorectal cancer screening, as suggested by Kanaoka
and co-workers [21,22].
For interpretation of quantitative mRNA measure-
ments in clinical samples, a proper normalization is an
essential component of reliable qPCR assays, which is
necessary to correct for sample differences in cellular
input, RNA quality and real-time efficiency [23]. Accord-
ing to recently published guidelines, normalization
against a single reference gene is not acceptable [24], since
large variations in the expression of commonly used
housekeeping genes have been described [23-27]. For in-
stance, in normal human colon samples, a more than 100
fold variation in GAPDH levels was reported; values var-
ied between 8 × 104 and 9.6 × 106 copies of GAPDH per
μg RNA [28]. In our study, COX-2 mRNA tumor/normal
ratios normalized with respect to GAPDH showed the
lowest correlation compared with normalization for tissue
weight.
As stated by de Kok et al. in [23], ideally normalization
could best be done based on the number of cells ana-
lyzed. In solid tissue, the amount of tissue is directly as-
sociated with cell numbers. Strikingly however, analysis
based on cell numbers or amount of tissue was not ap-
plied in any of the recent studies on COX-2 mRNA ex-
pression in colorectal tissue [12,14-18].
We quantified the COX-2 mRNA levels per mg tissue,
as well as relative to the levels of two different house-
keeping genes GAPDH and B2M, in 60 paired samples
of normal colorectal mucosa and corresponding non-
necrotic tumor tissue. Detectable levels of COX-2 mRNA
were found in all 60 paired specimens. After normalizing
of the COX-2 levels relative to tissue weight, the COX-2
levels were higher in 77% of the carcinoma tissue com-
pared to the adjacent normal mucosa, whereas the mean
COX-2 levels in the tumor were 21.6 times higher com-
pared to the normal mucosa levels. Since it is very simple
and accurate to determine the tissue weight just before
RNA extraction, this may be the method of choice, since
there is only a small weighing error (0.2-0.6%) when using
a precision weighing device.
Comparing the mRNA expression of the two com-
monly used housekeeping genes B2M and GAPDH, B2M
seems the second best choice for normalization in colo-
rectal tissue, since there is very much variation in the ex-
pression of GAPDH in normal colorectal tissue, as already
outlined above [28].
Conclusions
COX-2 mRNA levels as quantified by qPCR and normal-
ized with respect to tissue weight, are over-expressed in
77% of colorectal carcinomas compared to adjacent nor-
mal colorectal mucosa, and mean carcinoma levels are
almost 22 times higher than normal mucosa levels.
Normalization with respect to tissue weight is simple
and accurate, compared to normalization based on the
levels of the housekeeping genes B2M or GAPDH. The
common over-expression of COX-2 in colorectal carcin-
oma suggests a role for COX-2 as a colorectal carcinoma
risk biomarker, whereas attention should also be fo-
cussed on COX-2 inhibitors, as potential promising che-
mopreventive drugs for colorectal cancer.
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